Overview
Pharmaceutical

PeptiDream Inc.

PeptiDream is a Japan-based drug discovery powerhouse that leverages its proprietary Peptide Discovery Platform System (PDPS) to discover and develop novel peptide-based therapeutics through collaborative research, technology licensing, and strategic partnerships with global pharmaceutical companies and research institutions. The company also operates a radiopharmaceutical business through its wholly-owned subsidiary PDR Pharma, which researches, manufactures, and sells diagnostic radiopharmaceuticals (SPECT and PET agents) and therapeutic radiopharmaceuticals primarily in oncology. PeptiDream aims to serve as the central hub of a global peptide drug discovery network and ecosystem, advancing next-generation medicines that transform patient outcomes.

Market Cap
US$859M
¥136B
EV
US$802M
¥127B
StockUS$6.68(¥1,060)▼-4.50%
US$1 = ¥158.64 (2026-11-20)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
2.8
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-46.5%pt
100
Nov 25, 25 – Nov 20, 26StockTOPIX
MC → EV Bridge
US$859M¥136BMarket CapUS$103M¥16.4B+ DebtUS$149M¥23.6B− CashUS$11.8M¥1.87B− Inv. Sec.US$802M¥127BEV
AI Briefing
PeptiDream runs Japan's leading peptide drug discovery platform (PDPS), monetized via licensing deals with global pharma plus a radiopharma arm through PDR Pharma. FY25/12 revenue swung to US$117M (¥18.5B) with an operating loss of -US$31.5M (¥-5.0B), a sharp reversal from FY24/12's US$294M (¥46.7B) revenue and US$133M (¥21.1B) profit, underscoring lumpy, milestone-driven economics. Ownership remains concentrated among founders Kubota and Suga alongside trust banks, with no tender offer or research note in the data to flag a separate capital allocation storyline.
Performance & Balance
Revenue 5Y (US$)
US$59.0M¥9.37B'21/12US$169M¥26.9B'22/12US$181M¥28.7B'23/12US$294M¥46.7B'24/12US$117M¥18.5B'25/12
EBITDA 5Y (US$)
US$31.8M¥5.05B'21/12US$69.0M¥11.0B'22/12US$58.0M¥9.21B'23/12US$147M¥23.4B'24/12-US$18.2M¥-2.89B'25/12
Net Income 5Y (US$)
US$22.7M¥3.61B'21/12US$47.6M¥7.55B'22/12US$19.1M¥3.04B'23/12US$94.6M¥15.0B'24/12-US$23.6M¥-3.75B'25/12
Capital Structure
75%
25%
EquityD/E 0.34xDebt
Liquidity vs Debt 5Y (US$)▲ Net Cash
CashInv. Sec.Debt
US$99.3M¥15.8B'21/12US$33.1M¥5.25BUS$134M¥21.2B'22/12US$123M¥19.5BUS$141M¥22.4B'23/12US$303M¥48.1BUS$129M¥20.5B'24/12US$181M¥28.7BUS$112M¥17.8B'25/12
Business Segments
FY2025/12 · US$ (¥B)
86%
Radiopharmaceuticals Business
Revenue
US$106M(¥16.9B)
Segment profit
US$2.74M(¥0.43B)2.6%
14%
Drug Discovery and Development Business
Revenue
US$17.6M(¥2.79B)
Segment profit
-US$33.8M(¥-5.36B)-191.8%
Adjustments
Revenue
-US$7.26M(¥-1.15B)
Segment profit
—
No segment changes in the last 5 years
Shareholders
Top 10 hold 56.2%
1
The Master Trust Bank of Japan, Ltd. (Trust Account)
12.42%
2
Kiichi KUBOTA
9.50%
3
Hiroaki SUGA
9.18%
4
Custody Bank of Japan, Ltd. (Trust Account)
7.97%
5
STATE STREET BANK AND TRUST COMPANY 505301 (Standing Proxy: Mizuho Bank, Ltd.)
3.66%
6
Yutaka MURAKAMI
3.60%
7
Patrick REED
3.20%
8
HSBC BANK PLC A/C M AND G (ACS) VALUE PARTNERS CHINA EQUITY FUND (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
2.36%
9
BROWN BROTHERS HARRIMAN (LUXEMBOURG) SCA CUSTODI AN FOR ARCUS FUND SICAV - ARCUS JAPAN FUND (Standing Proxy: MUFG Bank, Ltd.)
2.25%
10
SBI SECURITIES Co., Ltd.
2.02%
Management
6 officers
Patrick REED
Representative Director, President
Aug 2003 Post-doctoral Fellow (NRSA), Dartmouth Medical School Apr 2004 Specially Appointed Associate Professor, Research Center for Advanced Science and Technology, The University of Tokyo Jan 2005 Visiting Associate Professor, International Center for Industry-Academia Collaboration, The University of Tokyo Apr 2006 Specially Appointed Associate Professor, International Center for Industry-Academia Collaboration, The University of Tokyo Jan 2007 Joined the Company Aug 2008 Director of the Company May 2012 Director, Head of R&D Division of the Company Sep 2012 Managing Director, Head of R&D Division of the Company Jul 2014 Managing Director, in charge of R&D Division of the Company Sep 2017 Representative Director, President of the Company Jan 2022 Representative Director, President and CEO of the Company (current) Mar 2025 Director, Peptistar Inc. (current) Mar 2026 Representative Director, President of the Company
1975-01-14
Masato MURAKAMI
Director, EVP, Radiopharmaceutical Business
Apr 2004 Fellow, Laboratory of Tumor Suppression, Institute of Medical Science, The University of Tokyo Jul 2006 Assistant Professor, Laboratory of Tumor Suppression, Institute of Medical Science, The University of Tokyo Apr 2007 Research Fellow, IFOM, The FIRC Institute of Molecular Oncology Foundation Aug 2010 Joined Novartis Institutes for Biomedical Research, Novartis Pharma AG, as Group Leader, Oncology Molecular Pathology Oct 2016 Joined Daiichi Sankyo Co., Ltd., Executive Medical Director, Research and Development Division Apr 2017 Vice President, Research and Development Division, and General Manager, Biomarker Promotion Department and Global Precision Medicine Department, Daiichi Sankyo Co., Ltd. Jan 2022 Joined the Company as CMO (current) Jul 2024 Representative Director, President, PDR Pharma Co., Ltd. (current) Dec 2024 Director, Peptaid Inc. Mar 2025 Representative Director, President, Peptaid Inc. (current) Mar 2026 Director, EVP, Radiopharmaceutical Business of the Company
1974-03-26
Kiichiro KAMIYA
Director, Full-time Audit and Supervisory Committee Member
Apr 1979 Joined Hoechst Japan Ltd. Jul 1988 Obtained MBA, University of Southern California, Marshall School of Business Feb 2001 Representative Director, President, ATMI Japan K.K. Sep 2013 Joined JSR Corporation; Executive Vice President, JSR Trading Co., Ltd. Sep 2014 Director, Executive Vice President, JSR Trading Co., Ltd. Apr 2015 Director, President, JSR Life Sciences Corporation Jun 2015 Executive Officer, JSR Corporation, and Director, President, JSR Life Sciences Corporation; Director, Institute of Medical Science and Biology Apr 2016 Executive Officer, Deputy General Manager, Life Sciences Business Division, JSR Corporation Jun 2017 Senior Executive Officer, Deputy General Manager, Life Sciences Business Division, JSR Corporation; Authorized Executive Officer, JSR Life Sciences Venture Capital LLC Jun 2022 Representative Director, President, Fastide Inc. (current) Mar 2025 Outside Director, Audit and Supervisory Committee Member of the Company (current)
1955-07-16
Yukinori HANABUSA
Director, Audit and Supervisory Committee Member
Apr 1998 Joined Aoyama Audit Corporation Jul 2001 Registered as Certified Public Accountant Aug 2009 Founded Accounting Works Co., Ltd., Representative Director (current) Mar 2015 Outside Audit & Supervisory Board Member, Arkland Service Co., Ltd. (now Arkland Service Holdings Co., Ltd.) Mar 2016 Outside Director, Audit and Supervisory Committee Member, same company Sep 2017 Outside Director, Audit and Supervisory Committee Member of the Company (current) May 2018 Outside Audit & Supervisory Board Member, Gift Co., Ltd. Jan 2019 Outside Director, Audit and Supervisory Committee Member, same company (current) Jun 2020 Outside Director, Aizawa Securities Co., Ltd. (now Aizawa Securities Group Co., Ltd.) Jun 2021 Outside Director, Audit and Supervisory Committee Member, same company (current)
1975-05-10
Junko UTSUNOMIYA
Director, Audit and Supervisory Committee Member
Apr 2000 Joined Nagashima Ohno & Tsunematsu Oct 2007 Seconded to Tokyo Stock Exchange, Inc. Nov 2011 Opened Utsunomiya Sogo Law Office Jun 2012 Outside Audit & Supervisory Board Member, START TODAY CO., LTD. (now ZOZO, Inc.) Apr 2013 Outside Audit & Supervisory Board Member, Solasto Corporation Sep 2013 Outside Director, Adventure Inc. Feb 2018 Managing Partner, Utsunomiya, Shimizu & Yorai Law Office (current) Oct 2018 Outside Audit & Supervisory Board Member, Raksul Inc. Oct 2019 Outside Director, Audit and Supervisory Committee Member, same company (current) Jun 2020 Outside Director, Heiwa Real Estate Co., Ltd. (current) Mar 2021 Outside Director, Audit and Supervisory Committee Member of the Company (current) Jun 2023 Outside Director, Audit and Supervisory Committee Member, ZOZO, Inc. (current)
1971-06-21
Junko NISHIYAMA
Director, Audit and Supervisory Committee Member
Apr 1979 Joined Lion Oil & Fat Co., Ltd. (now Lion Corporation) Mar 2006 General Manager, Product Purchasing Department, Purchasing Division, Lion Corporation Mar 2007 General Manager, Product Purchasing, Second Production Control Department, Production Division, Lion Corporation Jan 2009 Director, Packaging Technology Research Laboratory, R&D Division, Lion Corporation Jan 2014 General Manager, CSR Promotion Department, Lion Corporation Mar 2015 Full-time Audit & Supervisory Board Member, Lion Corporation Mar 2019 Advisor, Lion Corporation Mar 2019 Outside Director (Audit Committee Member), Ebara Corporation Jun 2019 Outside Director, Jaccs Co., Ltd. Jun 2020 Outside Audit & Supervisory Board Member, Toda Corporation (current) Mar 2021 Outside Director (Remuneration Committee Member), Ebara Corporation Mar 2024 Outside Director (Audit Committee Member), Ebara Corporation (current) Mar 2025 Outside Director, Audit and Supervisory Committee Member of the Company (current)
1957-01-10
Large Shareholding Reports
M&G Investment Management Limited
2026-10-07
9.54%→8.54%
Asset Management One Co., Ltd.
2026-06-22
3.86%→2.81%
Asset Management One Co., Ltd.
2026-03-23
3.86%
M&G Investment Management Limited
2026-03-23
8.50%→9.54%
Asset Management One Co., Ltd.
2025-09-22
4.54%→3.52%
Taiyo Pacific Partners L.P.
2025-02-06
5.11%→3.90%
Taiyo Pacific Partners L.P.
2025-01-31
6.18%→5.11%
Taiyo Pacific Partners L.P.
2024-11-06
7.20%→6.18%
Taiyo Pacific Partners L.P.
2022-09-05
6.16%→7.20%
Taiyo Pacific Partners L.P.
2022-08-02
5.14%→6.16%
Taiyo Pacific Partners L.P.
2022-06-23
5.14%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-11-11
Q3 Earnings Flash
FY ending Dec 2026
EDINET
2026-10-07
Large Shareholding Report
EDINET
2026-08-12
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-12
Q2 Earnings Flash
FY ending Dec 2026
EDINET
2026-06-22
Large Shareholding Report
TDnet
2026-05-13
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-23
Large Shareholding Report
EDINET
2026-03-23
Large Shareholding Report
EDINET
2026-03-18
Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2026-02-16
Full-Year Earnings Flash
FY ending Dec 2025
TDnet
2025-12-02
業績予想の修正
TDnet
2025-11-12
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-09-22
Large Shareholding Report
EDINET
2025-08-07
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-13
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2025-02-06
Large Shareholding Report
EDINET
2025-01-31
Large Shareholding Report
EDINET
2024-11-06
Large Shareholding Report
EDINETAmended
2024-09-25
Amended Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2024-08-09
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-15
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-04-01
Securities Registration Statement
EDINET
2024-03-28
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINETAmended
2023-11-09
Amended Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINETAmended
2023-11-09
Amended Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINETAmended
2023-07-18
Amended Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2023-05-12
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
Ask me!
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →